- Home
- FCO vs CRVO Comparison
FCO vs CRVO Comparison
Compare FCO & CRVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | FCO | CRVO |
|---|---|---|
| Founded | N/A | 2001 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 43.0M | 47.7M |
| IPO Year | 1994 | 2011 |
Fundamental Metrics
Financial Performance| Metric | FCO | CRVO |
|---|---|---|
| Price | $2.84 | $4.09 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $23.00 |
| AVG Volume (30 Days) | ★ 157.0K | 40.0K |
| Earning Date | 01-01-0001 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $4,006,510.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $2.73 | $3.51 |
| 52 Week High | $6.77 | $13.13 |
Technical Indicators
Market Signals| Indicator | FCO | CRVO |
|---|---|---|
| Relative Strength Index (RSI) | 35.04 | 47.19 |
| Support Level | $2.81 | $3.55 |
| Resistance Level | $3.06 | $4.41 |
| Average True Range (ATR) | 0.10 | 0.30 |
| MACD | -0.03 | 0.05 |
| Stochastic Oscillator | 4.42 | 58.37 |
Price Performance
Historical ComparisonAbout FCO abrdn Global Income Fund Inc.
abrdn Global Income Fund Inc is a closed-end, non-diversified management investment company. The Fund's principal investment objective is to provide high current income by investing predominantly in fixed-income securities. As a secondary investment objective, the Fund seeks capital appreciation, but only when consistent with its principal investment objective. It invests in Government Bonds & Corporate Bonds, and its investments are divided into three categories: Developed Markets, Investment Grade Developing Markets, and Sub-Investment Grade Developing Markets.
About CRVO CervoMed Inc.
CervoMed Inc is a clinical stage biotechnology company. It is focused on developing treatments for age-related neurologic disorders. The company's product candidate, Neflamapimod has the potential to treat and improve synaptic dysfunction, the reversible aspect of the underlying disease processes in DLB and certain other neurological disorders.